Breast intraductal proliferative lesion

Summary

Breast intraductal proliferative lesion (MONDO:0004007) is a disease. A subtype of intraductal breast neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	breast intraductal proliferative lesion
Mondo ID	MONDO:0004007
DOID	DOID:6839
NCIT	C27942
UMLS	C1334631
MedGen	277343
Is cancer (heuristic)	no

Also known as: DIN · ductal intraepithelial neoplasia · intraductal proliferative lesion · intraductal proliferative lesion of the breast · mammary intraepithelial neoplasia, ductal type

Disease family

This is a subtype of intraductal breast neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › breast disorder › breast neoplasm › intraductal breast neoplasm › breast intraductal proliferative lesion

Related subtypes (1): intraductal papillary breast neoplasm

Subtypes (3): flat ductal epithelial atypia, ductal breast carcinoma in situ, usual ductal breast hyperplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.